Christina Curtis

Christina Curtis has developed computational frameworks for understanding tumor evolution and heterogeneity that are essential for interpreting MRD signals in the context of clonal dynamics and treatment selection. Her integrative analyses of breast cancer molecular subtypes have revealed how residual disease composition predicts relapse patterns and therapeutic vulnerabilities. Her mathematical modeling approaches have been applied to optimize ctDNA sampling schedules and detection thresholds for MRD assays.